Loading clinical trials...
Loading clinical trials...
Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients
Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity. With the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
University Hospital of Zurich
Zurich, Canton of Zurich, Switzerland
Start Date
August 19, 2024
Primary Completion Date
October 31, 2027
Completion Date
October 31, 2027
Last Updated
April 10, 2025
130
ESTIMATED participants
Secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS)
DIAGNOSTIC_TEST
Lead Sponsor
University of Zurich
NCT06311227
NCT06285890
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00106925